Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.47 |
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.42 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | PGK2 | P07205 | 1/20 | 0.38 |
| ▸ | PHGDH | O43175 | 1/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.37 |
| ▸ | XPO1 | O14980 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31026307 | 1.00 | NOTUM (0.47) | NOTUMRAPGEF4PGK1PGK2PHGDH | |
| SCHEMBL16419769 | 0.83 | NOTUM (0.44) | NOTUMRAPGEF4PGK1PGK2PHGDH | |
| SCHEMBL1844641 | 0.82 | PGK1 (0.35) | NOTUMPGK1PGK2ALDH1A1MAPK1 | |
| SCHEMBL1082212 | 0.82 | NOTUM (0.50) | NOTUMACP1ALDH1A1S1PR1S1PR3 | |
| SCHEMBL131138 | 0.82 | NOTUM (0.50) | NOTUMRAPGEF4ACP1XPO1ALDH1A1 | |
| SCHEMBL107119 | 0.82 | RAPGEF4 (0.56) | NOTUMRAPGEF4PGK1PGK2XPO1 | |
| SCHEMBL130017 | 0.82 | RAPGEF4 (0.50) | NOTUMRAPGEF4PGK1PGK2XPO1 | |
| SCHEMBL1445873 | 0.79 | NOTUM (0.48) | NOTUMRAPGEF4ACP1XPO1ALDH1A1 | |
| SCHEMBL2745570 | 0.78 | POLB (0.41) | PGK1PGK2ALDH1A1MAPK1MAPT | |
| SCHEMBL34460149 | 0.78 | POLB (0.41) | PGK1PGK2ALDH1A1MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680601-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | Sanofi (FR) | 2026-01-21 | — | — | EP | disclosed |
| EP-4658654-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINES AND PYRAZOLO[1,5-D] [1,2,4]TRIAZINES AS NLRP3 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2025-12-10 | — | — | EP | disclosed |
| EP-4642784-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS AS INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4638438-A1 | ALPHA4 BETA7 INTEGRIN ANTAGONISTS AND USES THEREOF | Xinthera, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2025-08-28 | — | — | US | disclosed |
| US-20250206745-A1 | PYRROLOPYRIDAZINE DERIVATIVES AND RELATED USES | NODTHERA LTD (GB) | 2025-06-26 | — | — | US | disclosed |
| EP-4562009-A1 | NOVEL COMPOUNDS | AC Immune SA (CH) | 2025-06-04 | — | — | EP | disclosed |
| WO-2025099241-A1 | NLRP3 MODULATORS | EVOTEC INTERNATIONAL GMBH (DE) | 2025-05-15 | — | — | WO | disclosed |
| US-20250115558-A1 | PYRIDAZINE DERIVATIVES AND RELATED USES | NODTHERA LTD (GB) | 2025-04-10 | — | — | US | disclosed |
| CN-119732956-A | NLRP3 inflammatory corpuscle inhibitor | 诺华股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-7230133-B2 | Malonamides and malonamide derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-7230133-B2 | Malonamides and malonamide derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070099924-A1 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | JANSSEN SCIENCES IRELAND UC (IE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099924-A1 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | JANSSEN SCIENCES IRELAND UC (IE) | 2007-05-03 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-0084648-B1 | PROCESS FOR THE ISOMERIZATION OF ALKYLBENZOTRIFLUORIDES | BAYER AG (DE) | 1984-11-07 | — | — | EP | disclosed |
| US-4436941-A | Process for the isomerization of alkylbenzotrifluorides | BAYER AKTIENGESELLSCHAFT (DE) | 1984-03-13 | — | — | US | disclosed |
| EP-0084648-A1 | Process for the isomerization of alkylbenzotrifluorides | BAYER AG (DE) | 1983-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099924-A1 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-2, H1-4 | NOTUM 4739/4885RAPGEF4 4535/4885PGK1 2608/4885 |
| US-20250115558-A1 | PYRIDAZINE DERIVATIVES AND RELATED USES | IL1B, NLRP3, NOD1 | NOTUM 4504/4885RAPGEF4 1701/4885PGK1 928/4885 |
| US-20250206745-A1 | PYRROLOPYRIDAZINE DERIVATIVES AND RELATED USES | IL1B, NLRP3, NLRP1 | NOTUM 3516/4885RAPGEF4 1507/4885PGK1 1091/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | NOTUM 1888/4885RAPGEF4 4479/4885PGK1 2738/4885 |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | TYR, XDH, XPA | NOTUM 2503/4885RAPGEF4 4435/4885PGK1 1485/4885 |
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | NOTUM 4483/4885RAPGEF4 1224/4885PGK1 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.